Mawer Investment Management Ltd. increased its stake in shares of Allergan PLC. (NYSE:AGN) by 29.2% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 329,759 shares of the company’s stock after buying an additional 74,610 shares during the period. Mawer Investment Management Ltd. owned approximately 0.10% of Allergan PLC. worth $80,161,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Enterprise Financial Services Corp boosted its stake in shares of Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock worth $110,000 after buying an additional 178 shares in the last quarter. Jacobi Capital Management LLC boosted its stake in shares of Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after buying an additional 22 shares in the last quarter. JNBA Financial Advisors boosted its stake in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares in the last quarter. Webster Bank N. A. boosted its stake in shares of Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock worth $124,000 after buying an additional 123 shares in the last quarter. Finally, Pacific Center for Financial Services boosted its stake in shares of Allergan PLC. by 805.1% in the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after buying an additional 475 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Allergan PLC. (NYSE AGN) opened at 223.94 on Tuesday. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The stock has a market cap of $74.86 billion, a P/E ratio of 6.82 and a beta of 1.16. The stock has a 50 day moving average of $240.49 and a 200-day moving average of $238.48.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the business earned $3.35 earnings per share. Analysts anticipate that Allergan PLC. will post $16.27 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.25%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is 9.95%.

WARNING: This report was first posted by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/allergan-plc-agn-shares-bought-by-mawer-investment-management-ltd/1528879.html.

A number of analysts recently weighed in on the stock. Vetr upgraded shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price target for the company in a research note on Monday, June 26th. UBS AG reiterated a “buy” rating and set a $275.00 price target on shares of Allergan PLC. in a research note on Monday, May 15th. Wells Fargo & Company reiterated an “outperform” rating and set a $280.00 price target (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. Royal Bank Of Canada increased their price target on shares of Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 10th. Finally, Goldman Sachs Group, Inc. (The) cut shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target for the company. in a research note on Wednesday, May 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $275.49.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.